Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
0.00% $0.686
America/New_York / 19 apr 2023 @ 15:58
FUNDAMENTALS | |
---|---|
MarketCap: | 7.38 mill |
EPS: | -19.14 |
P/E: | -0.0358 |
Earnings Date: | May 02, 2023 |
SharesOutstanding: | 10.77 mill |
Avg Daily Volume: | 0.208 mill |
RATING 2023-05-23 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0358 | sector: PE 15.43 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.0358 | industry: PE 102.44 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ -0.0820 - 0.138 ( +/- 392.86%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-11-17 | Chapman John C | Buy | 20 000 | Common Stock |
2022-11-10 | Lepore Patrick G | Buy | 100 000 | Common Stock |
2022-11-10 | Crew Timothy C | Buy | 15 000 | Common Stock |
2022-09-14 | Rewolinski Melissa | Buy | 31 159 | Common stock |
2022-09-07 | Kozlowski John | Sell | 775 | Common Stock |
INSIDER POWER |
---|
61.25 |
Last 94 transactions |
Buy: 1 406 485 | Sell: 297 663 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.686 (0.00% ) |
Volume | 0.281 mill |
Avg. Vol. | 0.208 mill |
% of Avg. Vol | 134.76 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.